Prime Medicine is a technology company.
Prime Medicine has raised $320.0M across 2 funding rounds.
Prime Medicine has raised $320.0M in total across 2 funding rounds.
Prime Medicine has raised $320.0M in total across 2 funding rounds.
Prime Medicine's investors include Accel, ARCH Venture Partners, Arrive, Better Tomorrow Ventures, CentreGold Capital, Dreamers VC, Footprint Coalition, F-Prime Capital Partners, General Catalyst, Daniel Lynch, GV (Google Ventures), GV.
Prime Medicine is a biotechnology company developing one-time curative gene editing therapies using its proprietary Prime Editing platform, which precisely "searches and replaces" disease-causing genetic mutations without double-strand DNA breaks.[1][2][5] It targets high-value programs in hematology, immunology & oncology, liver, and lung diseases, serving patients with genetic disorders like chronic granulomatous disease (CGD), Wilson’s Disease, and cystic fibrosis, while addressing limitations of prior gene editing tools to potentially treat ~90% of known mutations.[1][2][6] The company is advancing clinical-stage assets, including the Phase 1/2 Prime-0101 trial for PM359 in p47phox CGD, with partnerships like Bristol Myers Squibb for ex vivo T-cell therapies and the Cystic Fibrosis Foundation.[3][6]
Growth momentum includes NASDAQ listing (PRME), a recent New England Journal of Medicine publication on PM359 data (December 2025), and a diversified pipeline expanding into neurological, ocular, and other areas, backed by initial 2019 investments and $315M Series B financing.[2][3][5][6]
Prime Medicine was founded in 2019-2020 in Cambridge, MA, spun out from Dr. David R. Liu’s lab at the Broad Institute of MIT and Harvard, where Prime Editing was invented and published in *Nature* (December 2019).[2][3][4][5] Key figures include co-founder Andrew Anzalone, MD, PhD (head of platform), CEO Keith Gottesdiener, MD (prior gene therapy leader at Spark Therapeutics), and scientific founder David Liu (pioneer of base editing and other tools).[3][4][5] Early traction came from F-Prime Capital's 2019 investment, recognizing the platform's potential for precise editing, followed by rapid Series B funding in 2021 to advance preclinical programs.[3][5] Pivotal moments include launching operations in summer 2020, entering clinical trials with PM359, and recent 2024-2025 partnerships and data publications.[2][6]
Prime Medicine rides the gene editing revolution, expanding beyond CRISPR's limitations amid surging demand for precision therapies in a $20B+ genetic medicines market driven by aging populations and rare disease awareness.[2][5] Timing aligns with FDA approvals for prior gene therapies (e.g., Luxturna) and maturing delivery tech like LNPs/AAVs, positioning Prime Editing as a next-gen tool for intractable mutations.[1][4][6] Market forces favoring it include regulatory paths for well-defined rare diseases, partnerships de-risking development (e.g., BMS, CF Foundation), and its potential to influence ecosystem-wide adoption by enabling broader, safer edits for common diseases and cancers.[3][6]
Prime Medicine's clinical momentum—led by PM359 data and pipeline expansion—positions it for potential IND filings, Phase 2 readouts, and partnership milestones in 2026+, with Prime Editing's modularity enabling rapid pivots to neurology, hearing loss, and ex vivo cell therapies.[2][6] Trends like AI-optimized editors, improved delivery, and reimbursement models for one-time cures will accelerate its path, potentially evolving it into a gene editing powerhouse akin to CRISPR pioneers. As a leader in precise genome engineering, Prime Medicine exemplifies biotech's shift toward transformative, mutation-agnostic therapies, fulfilling its founding promise to patients.[2][3][5]
Prime Medicine has raised $320.0M across 2 funding rounds. Most recently, it raised $200.0M Series B in July 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2021 | $200.0M Series B | Accel, ARCH Venture Partners, Arrive, Better Tomorrow Ventures, CentreGold Capital, Dreamers VC, Footprint Coalition, F-Prime Capital Partners, General Catalyst, Daniel Lynch, GV (Google Ventures), GV, Heroic Ventures, Nextech Invest, Plug & Play Ventures, Sequoia Capital, Julian Zegelman, Munish Varma | |
| Oct 1, 2019 | $120.0M Series A | Accel, ARCH Venture Partners, Arrive, Better Tomorrow Ventures, CentreGold Capital, Dreamers VC, Footprint Coalition, F-Prime Capital Partners, General Catalyst, Daniel Lynch, GV (Google Ventures), GV, Heroic Ventures, Nextech Invest, Plug & Play Ventures, Sequoia Capital, Julian Zegelman, Munish Varma |